Literature DB >> 11932297

Supraphysiological doses of GH induce rapid changes in cardiac morphology and function.

Antonio Cittadini1, Annika Berggren, Salvatore Longobardi, Christer Ehrnborg, Raffaele Napoli, Thord Rosén, Serafino Fazio, Kenneth Caidahl, Bengt-Ake Bengtsson, Luigi Saccà.   

Abstract

GH is an agent widely used in sport to improve physical performance and has been proposed as adjunctive therapy in several clinical conditions. However, its short-term effects on the normal human heart are poorly understood. Sixty young normal volunteers (30 males and 30 females) were enrolled in a multicenter, double-blind, placebo-controlled study. All subjects were randomized to receive GH (0.03 or 0.06 mg/kg.d) or placebo. A complete Doppler-echocardiographic examination was performed at baseline and after 4 wk of treatment. Low-dose GH did not significantly affect echocardiographic parameters. In contrast, high-dose GH increased left ventricular mass index by 12% (P < 0.05). The type of growth response was concentric, because left ventricular wall thickness but not diameter increased, leading to a 10% increase of relative wall thickness. These structural changes were associated with functional changes, including a significant increase in cardiac index and a decrease in peripheral vascular resistance; diastolic function was not altered. Fractional shortening and systemic blood pressure were unchanged in the two treatment groups. In conclusion, administration of GH for 4 wk at doses that simulate GH abuse in sport caused a high cardiac output state associated with concentric left ventricular remodeling.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11932297     DOI: 10.1210/jcem.87.4.8363

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Idiopathic adult growth hormone deficiency.

Authors:  Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

2.  Availability and quality of illegitimate somatropin products obtained from the Internet.

Authors:  Róbert György Vida; András Fittler; Ivett Mikulka; Eszter Ábrahám; Viktor Sándor; Ferenc Kilár; Lajos Botz
Journal:  Int J Clin Pharm       Date:  2016-11-25

3.  Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction.

Authors:  Aaron L Baggish; Rory B Weiner; Gen Kanayama; James I Hudson; Michael H Picard; Adolph M Hutter; Harrison G Pope
Journal:  Circ Heart Fail       Date:  2010-04-27       Impact factor: 8.790

4.  Human growth hormone abuse in male weightlifters.

Authors:  Brian P Brennan; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Am J Addict       Date:  2010-11-12

Review 5.  Growth hormone (GH): usage and abuse.

Authors:  Almira Hadzović; Emina Nakas-Ićindić; Elma Kucukalić-Selimović; Abdul-Umid Salaka
Journal:  Bosn J Basic Med Sci       Date:  2004-10       Impact factor: 3.363

6.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

7.  The effects of growth hormone and/or testosterone on whole body protein kinetics and skeletal muscle gene expression in healthy elderly men: a randomized controlled trial.

Authors:  Manthos G Giannoulis; Nicola Jackson; Fariba Shojaee-Moradie; K Sreekumaran Nair; Peter H Sonksen; Finbarr C Martin; A Margot Umpleby
Journal:  J Clin Endocrinol Metab       Date:  2008-05-13       Impact factor: 5.958

8.  Growth hormone treatment and left ventricular dimensions in Turner syndrome.

Authors:  Lea Ann Matura; Vandana Sachdev; Vladimir K Bakalov; Douglas R Rosing; Carolyn A Bondy
Journal:  J Pediatr       Date:  2007-06       Impact factor: 4.406

Review 9.  The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency.

Authors:  Kennett Sprogøe; Eva Mortensen; David B Karpf; Jonathan A Leff
Journal:  Endocr Connect       Date:  2017-09-25       Impact factor: 3.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.